Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Growth Metrics

Others

Bioregenx (BRGX) Amortization of Deferred Charges (2024 - 2025)

Bioregenx's Amortization of Deferred Charges history spans 2 years, with the latest figure at $1976.0 for Q3 2025.

Quarterly results put Amortization of Deferred Charges at $1976.0 for Q3 2025, down 77.05% from a year ago — trailing twelve months through Dec 2025 was $2295.0 (down 95.38% YoY), and the annual figure for FY2025 was $2295.0, down 95.38%.
Amortization of Deferred Charges for Q3 2025 was $1976.0 at Bioregenx, up from -$1196.0 in the prior quarter.
In the past five years, Amortization of Deferred Charges ranged from a high of $16213.0 in Q4 2024 to a low of -$1196.0 in Q2 2025.